Meeder Asset Management Inc Uni Qure N.V. Transaction History

Meeder Asset Management Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$16.98 - $25.54 $16,640 - $25,029	-980 Reduced 28.35%	2,477 $46,000
Q2 2022 Aug 08, 2022	BUY	$13.15 - $20.45 $25,563 - $39,754	1,944 Added 128.49%	3,457 $64,000
Q1 2022 May 10, 2022	BUY	$14.54 - $21.5 $21,999 - $32,529	1,513 New	1,513 $27,000
Q4 2021 Feb 11, 2022	SELL	$20.24 - $36.01 $607 - $1,080	-30 Closed	0 $0
Q3 2021 Nov 08, 2021	BUY	$26.01 - $38.22 $702 - $1,031	27 Added 900.0%	30 $1,000
Q1 2021 Apr 28, 2021	SELL	$29.24 - $42.03 $233 - $336	-8 Reduced 72.73%	3 $0
Q4 2020 Feb 09, 2021	SELL	$35.35 - $50.67 $1,131 - $1,621	-32 Reduced 74.42%	11 $0
Q2 2020 Aug 11, 2020	SELL	$45.06 - $67.74 $90 - $135	-2 Reduced 4.44%	43 $2,000
Q1 2020 May 15, 2020	BUY	$40.01 - $73.97 $80 - $147	2 Added 4.65%	45 $2,000
Q4 2019 Feb 13, 2020	BUY	$37.13 - $74.62 $1,596 - $3,208	43 New	43 $3,000

142

35.3M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Meeder Asset Management Inc with notifications on news.